Orchestra BioMed Holdings
London, England, United Kingdom · Biotechnology, Health Care, Manufacturing
Orchestra BioMed Holdings, Inc. is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Its lead product candidate is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, and it is also developing Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of ather
Key facts
- Headquarters
- London, England, United Kingdom
- Employees
- 70
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (OBIO)
- Website
- www.orchestrabiomed.com
- Company page
Recent activity at Orchestra BioMed Holdings
- : SEC 8-K (7.01): On October 1, 2026, Orchestra BioMed Holdings, Inc. issued a press release announcing that it exceeded the enrollment target in the BACKBEAT Global Pivotal Trial of its AVIM Therapy. This event is significant as it suggests positive progress in their clinical trial, which could impact future developments and investor confidence. The announcement indicates strong performance in achieving trial recruitment objectives, which is crucial for the advancement of the therapy towards regulatory approval. The release serves as a Regulation FD disclosure and can be found in Exhibit 99.1 attached to this report.
- : SEC 8-K (7.01):
- : SEC 8-K (5.07): On June 23, 2026, Orchestra BioMed Holdings, Inc. held its 2026 Annual Meeting of Stockholders where stockholders voted on five proposals. A total of 59,880,715 shares were entitled to vote, with 49,053,298 shares represented at the meeting. The proposals included the election of directors, among other corporate matters as outlined in the definitive proxy statement filed prior to the meeting. This meeting is critical for determining governance and electing leadership within the company, influencing future strategic decisions.
- : Orchestra BioMed Secures $15 Million Investment from Ligand as Part of Strategic Financing Agreement.
- : SEC 8-K (5.02): On February 12, 2026, the Board of Directors of Orchestra BioMed Holdings, Inc. approved the 2026 cash bonus plan for all executive officers, which establishes annual goals and performance metrics with mid-year deliverables. The plan allows for the payment of up to 25% of annual bonuses in Q3 2026 based on the achievement of goals set by the Board. Key objectives include enrollment targets for the BACKBEAT global pivotal study and the Virtue SAB pivotal study, along with certain financial metrics. If the 2026 Goals and Objectives are fully achieved, bonuses will be paid at 100% of the target, with additional potential for bonuses based on achieving stretch goals. This strategic planning indicates a focus on operational metrics critical for the company's future growth and partnership expansion.
- : SEC 8-K (5.02): On February 12, 2026, Orchestra BioMed Holdings, Inc. approved a new cash bonus plan for all executive officers, following a recommendation by the Compensation Committee. The plan includes annual performance goals and mid-year key deliverables, with a provision for a mid-year performance review based on measurable metrics, allowing for the payment of up to 25% of annual bonuses in the third quarter of 2026. This new structure offers the Compensation Committee discretion to adjust full year goals, reinforcing the management's focus on achieving strategic objectives and performance outcomes throughout the year.
- : SEC 8-K (8.01): On January 12, 2026, Orchestra BioMed Holdings, Inc. announced via a press release that it would receive up to $21 million in proceeds from the acquisition of Vivasure by Haemonetics. This acquisition represents a significant business development for Orchestra BioMed, highlighting a strategic partnership that could enhance its market position and financial strength. The press release serves to inform investors and stakeholders about this important transaction and its potential implications for future operations.
- : SEC 8-K (7.01): On November 12, 2025, Orchestra BioMed Holdings, Inc. held a conference call to discuss important updates related to the Company's clinical, strategic, and financing developments. The call included the presentation of a Transcript and an Investor Presentation, both of which were included as exhibits in the filing. The conference call serves as a significant disclosure of the Company's recent activities and initiatives relevant to investors. The details shared may have strategic implications on the Company's direction and investor confidence.
- : SEC 8-K (7.01): On November 12, 2025, Orchestra BioMed Holdings, Inc. held a conference call to discuss significant business updates related to clinical, strategic, and financing developments. This conference marks a strategic communication effort by the Company to inform stakeholders of recent advancements and future plans. The transcripts and investor presentations that were provided highlight the importance of these updates in the context of the Company's growth and future directions. As an emerging growth company, these disclosures are particularly relevant for investors looking to gauge the company's trajectory and how it plans to navigate upcoming challenges.
- : SEC 8-K (7.01):
Orchestra BioMed Holdings in the news
- Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference - GlobeNewswire (Aug 20, 2026)
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance (Sep 02, 2026)
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates - GlobeNewswire (Aug 10, 2026)
- Orchestra BioMed to Host R&D Day Featuring Clinical - GlobeNewswire (Oct 22, 2026)
- Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy - GlobeNewswire (Oct 01, 2026)
- Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics - GlobeNewswire (Sep 15, 2026)
- Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026 - GlobeNewswire (Sep 16, 2026)
- Orchestra BioMed Announces Proposed Public Offering - GlobeNewswire (Jul 31, 2025)
Companies similar to Orchestra BioMed Holdings
- Bedfont® Scientific Limited · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- OsteoCentric · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- MTD Group · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- IceCure Medical · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- FAMECO Group ApS · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
About Orchestra BioMed Holdings: questions and answers
What does Orchestra BioMed Holdings do?
Orchestra BioMed Holdings, Inc. is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Its lead product candidate is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, and it is also developing Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of ather
Where is Orchestra BioMed Holdings headquartered?
Orchestra BioMed Holdings is headquartered in London, England, United Kingdom.
How many employees does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has about 70 employees.
What is the latest news on Orchestra BioMed Holdings?
On Oct 01, 2026, SEC 8-K (7.01): On October 1, 2026, Orchestra BioMed Holdings, Inc. issued a press release announcing that it exceeded the enrollment target in the BACKBEAT Global Pivotal Trial of its AVIM Therapy. This event is significant as it suggests positive progress in their clinical trial, which could impac
Is Orchestra BioMed Holdings a public company?
Yes. Orchestra BioMed Holdings is publicly traded under the ticker OBIO.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy